Savant Capital’s Medifast MED Stock Holding History

Savant Capital’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,513	Closed	-$273K	–	1437
2024 Q2	$273K	Buy	+12,513	New	+$334K	﹤0.01%	1013

Other funds holding MED

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Savant Capital's MED Position: Q3 2024 in Review

Savant Capital sold out of Medifast (MED) in Q3 2024, closing a stake of 12,513 shares — an estimated $273K sold.

Savant Capital first reported a position in MED in Q2 2024 and held it in 1 quarter. The position peaked at $273K in Q2 2024. 140 funds tracked by Wall St. Rank hold MED as of Q3 2024.

Savant Capital reported no remaining Medifast position as of Q3 2024 after selling out during the quarter.
Savant Capital sold 12,513 Medifast shares in Q3 2024, an estimated $273K.
Savant Capital first reported a position in Medifast in Q2 2024 and held it in 1 quarter.
Savant Capital's Medifast position peaked at $273K in Q2 2024.
140 funds tracked by Wall St. Rank held Medifast as of Q3 2024.

Based on Savant Capital's 13F filing for Q3 2024, filed 4 Nov 2024.